Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. aptacheck

AptaCheck

Bioelectronic lab-on-a-chip for point-of-care detection of infectious agents

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 AptaCheck project word cloud

Explore the words cloud of the AptaCheck project. It provides you a very rough idea of what is the project "AptaCheck" about.

cutting    8m    easily    adequately    approved    pathogens    point    minutes    gastroenteritis    human    approvals    simplicity    quality    platform    departments    versatile    scalable    jobs    turnover    biochips    financing    strategic    patients    automated    qr    detection    flu    clinics    optimisation    communication    data    disposable    isolated    antibody    lab    consolidated    outbreaks    time    wifi    3bn    industry    special    microbiological    pcr    detecting    samples    mover    complete    scanner    transfer    chain    fast    manufacturing    electronic    eventual    downstream    2024    poc    reader    lower    accurate    revenues    markets    supply    action    instability    hospitals    aptamer    infections    observation    diagnosis    drawbacks    clinically    aptachek    15    beats    direct    obligatory    portability    skills    74    care    wireless    edge    chip    enter    advantage    identifications    secure    overcome    infectious    equipped    handling    600    immediately    aptacheck    diagnostics    semi    first    elisa    preventing    industrial    display    later    house    market    groundbreaking    clinical    drug    parallel    cumulative    linked    biosensor    accuracy    2020   

Project "AptaCheck" data sheet

The following table provides information about the project.

Coordinator		 SOLSTEN DIAGNOSTICS AS 

Organization address
address: HEDEAGER 40
city: AARHUS N
postcode: 8200
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Denmark [DK]
 Project website https://solsten-diag.com
 Total cost 2˙254˙187 €
 EC max contribution 1˙577˙931 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SOLSTEN DIAGNOSTICS AS DK (AARHUS N) coordinator 1˙577˙931.00

Map

 Project objective

AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer. AptaCheck beats the state of the art: - Cost: The disposable chip will cost the end user €10 - Time: Turnover-time is less than 15 minutes including sample handling - Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR - Simplicity: No special equipment or skills are needed - Portability: The hand-held reader and biochips can be used at the point of care - Communication: AptaCheck will be linked to electronic lab systems via wireless communication - Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks - Versatile: AptaCheck can easily be adapted to detection of new pathogens. We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips. AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc. With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals. In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.

 Deliverables

List of deliverables.
Portfolio of communication material Other 2020-02-18 15:41:04

Take a look to the deliverables list in detail:  detailed list of AptaCheck deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "APTACHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "APTACHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More  

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More